Clinical Trial Search

Primary: Number of Participants With Niche Visualized by Saline Infusion Sonography — 40; 53; 25; 23 Participants — p=0.05

Primary: Placenta Previa — 18; 17; 0; 3 Participants

Primary: Cesarean Scar Defect in the Uterine Incisional Line — 12; 39 participants — p=0.0001

Primary: Incision Time . — 271.5; 188.17 Seconds — p=<0.001

Primary: Number of Participants With Absence of Newly Formed Intrauterine Adhesions Following RF Ablation of Fibroids — 34 Participants

Primary: Quantitative Blood Loss — 641.8; 596.5 mL

Primary: Suture Location in Relation to the Surrounding Anatomy — 2.5; 2.8; 2.2; 2.2 cm

Primary: Blood Loss — 616; 418; 141; 106 cc

Primary: Percentage of Subjects With ≥ 50% Reduction in Menstrual Blood Loss as Assessed by Pictorial Blood Loss Assessment Chart (PBAC) — 64.8 percentage of participants

Primary: Clinical Pregnancy Rate

Primary: Safety (Adverse Events) — 0 device related adverse event

Primary: Measurement of Uterine Artery Pulsatility Index — 2.40; 2.35 index — p=<0.05

Primary: Percentage of Patients Who Develop a Surgical Site Infection — 14; 15 Participants — p=<0.05

Primary: mg Equivalent Morphine Used Until Discharge From Recovery Room to Control Pain Level Below 4/10 (VAS) — 11; 5.1 mg

Primary: Incidence of Adhesions — 75.6; 75.9 percentage of patients with adhesions

Primary: Assessment of Menstrual Blood Flow (MBF) at 12 Months Post Procedure — 40.2; 48.8; 59.1; 67.7 Percentage of participants

Primary: Rates of Uterine Perforation — 0 Number of cases

Primary: Subjective Cosmetic Result — 13; 26.5 units on a scale

Primary: Number of Participants With Pregnancy in Loop-shaped Intrauterine Device Group and Intrauterine Balloon Group — 12; 22 participants — p=0.009

Primary: Improvement of Surgical Scars at 12 Months Compared to Baseline (Pre-treatment) as Evaluated by 3 Independent Blinded Reviewers Using the General Aesthetic Improvement…

Primary: Number of Adverse Events — 1 Participants

Primary: Patient-perceived Pain — 3; 4 score on a scale — p=0.21

Primary: Successful Retention of IUD — 7 participants

Primary: Patient and Observer Scar Assessment Scale (POSAS) - PI Assessment — 4.4; 4.5 score on a scale

Primary: Patient and Observer Scar Assessment Scale (POSAS)- Patient Scores 12M — 1.09; 1.22; 1.3; 1.87 score on a scale

Primary: Number of Participants With Wound Complications (Surgical Site Infection (SSI), Hematoma, Separation, Seroma, Etc) — 23; 37; 16; 25 Participants — p=0.04

Primary: Feasibility: Proportion of Eligible Patients Who Agree to Participate in the Study. — 60 Participants

Primary: MMSS for Scar Halves Treated — 8.4; 8.7 score on a scale

Primary: Evaluation of All Adverse Events Encountered — 0; 0.95 Adverse Device Effects / patient

Primary: To Determine if the LigaSure Device, Which we Routinely Used for Removal of Tubes and Ovaries, is Effective at Destroying All Tubal Cells Comprising the Fallopian Tube…